Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Lê MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J. Lê MP, et al. Among authors: duvivier c. J Antimicrob Chemother. 2017 Nov 1;72(11):3167-3171. doi: 10.1093/jac/dkx275. J Antimicrob Chemother. 2017. PMID: 28961979
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG; ROCnRAL ANRS 157 Study Group. Katlama C, et al. Among authors: duvivier c. J Antimicrob Chemother. 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536. Epub 2014 Feb 16. J Antimicrob Chemother. 2014. PMID: 24535278 Clinical Trial.
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group. Lê MP, et al. Among authors: duvivier c. J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26. J Antimicrob Chemother. 2015. PMID: 25917348 Clinical Trial. No abstract available.
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S, Meynard JL, Valantin MA, Molina JM, Flandre P, Katlama C, Calvez V, Marcelin AG. Lambert-Niclot S, et al. Among authors: duvivier c. Antimicrob Agents Chemother. 2010 Nov;54(11):4910-3. doi: 10.1128/AAC.00725-10. Epub 2010 Aug 16. Antimicrob Agents Chemother. 2010. PMID: 20713677 Free PMC article. Clinical Trial.
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group. Slama L, et al. Among authors: duvivier c. J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103. Epub 2016 Apr 10. J Antimicrob Chemother. 2016. PMID: 27068399 Clinical Trial.
Detectable HIV-RNA in semen of HIV controllers.
Chaix ML, Boufassa F, Meyzer C, Leruez-Ville M, Mahjoub N, Nere ML, Genet P, Duvivier C, Lascoux-Combes C, Lambotte O, Ghosn J. Chaix ML, et al. Among authors: duvivier c. PLoS One. 2017 Aug 16;12(8):e0183376. doi: 10.1371/journal.pone.0183376. eCollection 2017. PLoS One. 2017. PMID: 28813503 Free PMC article.
"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.
Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, Duvivier C, Launay O, Karmochkine M, Arvieux C, Ménard A, Piroth L, Canestri A, Trias D, Peytavin G, Landman R, Ghosn J; Coferal-IMEA048 Study Group. Gantner P, et al. Among authors: duvivier c. PLoS One. 2019 Apr 24;14(4):e0216010. doi: 10.1371/journal.pone.0216010. eCollection 2019. PLoS One. 2019. PMID: 31017957 Free PMC article.
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D; members of the ANRS 163 ETRAL study. Katlama C, et al. J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224. J Antimicrob Chemother. 2019. PMID: 31269208
392 results